| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Over the last 12 months, insiders at Celularity Inc. have bought $0 and sold $0 worth of Celularity Inc. stock.
On average, over the past 5 years, insiders at Celularity Inc. have bought $4.24M and sold $23.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 21,410,983 shares for transaction amount of $5.33M was made by Lim Kok Thay (10 percent owner) on 2024‑01‑12.
| 2024-01-12 | Lim Kok Thay | 10 percent owner | 21.41M 11.8762% | $0.25 | $5.33M | +38.71% | ||
| 2023-10-05 | Sale | Sorrento Therapeutics, Inc. | 10 percent owner | 6.31M 21.0749% | $1.50 | $9.46M | +42.18% | |
| 2023-10-05 | Hariri Robert J | Chief Executive Officer | 9.36M 3.306% | $0.16 | $1.48M | +42.18% | ||
| 2023-09-29 | Sale | Sorrento Therapeutics, Inc. | 10 percent owner | 9.06M 30.2885% | $1.50 | $13.6M | +35.14% | |
| 2023-09-29 | Hariri Robert J | Chief Executive Officer | 9.06M 3.3418% | $0.17 | $1.5M | +35.14% | ||
| 2022-11-30 | Hariri Robert J | Chief Executive Officer | 10,000 0.0383% | $1.72 | $17,175 | -66.08% | ||
| 2022-11-29 | Hariri Robert J | Chief Executive Officer | 40,000 0.1524% | $1.71 | $68,400 | -65.27% | ||
| 2022-11-28 | Hariri Robert J | Chief Executive Officer | 40,000 0.155% | $1.74 | $69,600 | -64.36% |
| Lim Kok Thay | 10 percent owner | 51473762 214.9289% | $119.93M | 1 | 0 | +38.71% |
| Hariri Robert J | Chief Executive Officer | 28570434 119.296% | $66.57M | 5 | 0 | <0.0001% |
| Sorrento Therapeutics, Inc. | 10 percent owner | 5050427 21.0881% | $11.77M | 0 | 2 |
$4,613,182 | 103 | -36.00% | $55.16M | |
$15,973,675 | 54 | 5.25% | $51.75M | |
$81,638,324 | 48 | 7.58% | $59.48M | |
$77,062,892 | 41 | 13.96% | $54.31M | |
$18,752,549 | 33 | -28.39% | $56.5M | |
$241,165 | 22 | -16.72% | $57.09M | |
$160,539,875 | 21 | -6.57% | $58.76M | |
$1,087,418 | 21 | 1.95% | $58.82M | |
$167,476,357 | 20 | -1.54% | $55.44M | |
$32,972,199 | 16 | -10.77% | $58.99M | |
$245,302 | 15 | -4.08% | $60.89M | |
$91,209,456 | 15 | -7.00% | $51.16M | |
$18,535,159 | 14 | 57.32% | $57.07M | |
$932,835 | 14 | -19.33% | $52.23M | |
$3,682,258 | 10 | -34.11% | $54.11M | |
$43,326,461 | 6 | 16.01% | $51.7M | |
Celularity Inc. (CELU) | $8,470,804 | 6 | -13.28% | $55.8M |
$195,184 | 5 | 6.34% | $56.46M | |
$32,000,000 | 3 | -41.00% | $51.7M |
| Increased Positions | 11 | +35.48% | 181,348 | +9.8% |
| Decreased Positions | 8 | -25.81% | 69,716 | -3.77% |
| New Positions | 3 | New | 105,341 | New |
| Sold Out Positions | 5 | Sold Out | 60,702 | Sold Out |
| Total Postitions | 34 | +9.68% | 2M | +6.03% |
| C V Starr & Co Inc | $1,219.00 | 3.18% | 764,069 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $798.00 | 2.08% | 500,132 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $210.00 | 0.55% | 131,510 | -5,964 | -4.34% | 2024-12-31 |
| Blackrock, Inc. | $161.00 | 0.42% | 101,180 | -471 | -0.46% | 2025-03-31 |
| State Street Corp | $104.00 | 0.27% | 65,430 | +38,800 | +145.7% | 2024-12-31 |
| Two Sigma Investments, Lp | $72.00 | 0.19% | 44,914 | +44,914 | New | 2024-12-31 |
| Hb Wealth Management, Llc | $64.00 | 0.17% | 40,100 | +4,260 | +11.89% | 2024-12-31 |
| Biltmore Family Office, Llc | $56.00 | 0.15% | 35,000 | +35,000 | New | 2024-12-31 |
| Northern Trust Corp | $54.00 | 0.14% | 34,062 | 0 | 0% | 2024-12-31 |
| Keynote Financial Services Llc | $40.00 | 0.1% | 25,023 | +11,863 | +90.14% | 2024-12-31 |